Nova Eye Medical AI Stock Analysis
Want to see AU:EYE full AI Analyst Report?
Nova Eye Medical (EYE) AI Stock Analysis
Nova Eye Medical
(ASX:EYE)
The overall score of 57 reflects a company with improving operational metrics but significant fundamental risks. The primary strength is a solid balance sheet with low debt, providing a runway for the company. Improving gross margins and revenue growth are positive signals. However, the persistent lack of profitability and negative cash flows are major concerns, weighing heavily on the score. The technical trend is mildly positive, but the negative P/E ratio underscores the company's current lack of earnings.
Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 4.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 190.27K
- Price to Earnings (P/E)
- -10.2
- Beta (1Y)
- 0.74
- Revenue Growth
- 19.13%
- EPS Growth
- 58.47%
- Country
- Australia
- Employees
- 301
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Nova Eye Medical Business Overview & Revenue Model
Company Description
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease i...
Nova Eye Medical Earnings Call Summary
The call emphasized strong top‑line growth (26% YoY revenue), achievement of profitability in H2 FY'26 and clear U.S. momentum (30% U.S. growth, ~20k procedures/year, high revenue per rep). Product approvals (FDA, MDR) and recent product enhancements (Shear Clear, Green Light) support ongoing adoption, and management stated liquidity is sufficient to fund FY'27 guidance. Lowlights are mostly manageable: a small but visible China decline (‑18% on a small base), a deliberate winding down of the 2RT program reducing R&D spend, continued low overall market share (~4%) and a relatively wide FY'27 guidance range reflecting execution uncertainty. Overall, the positive operational and financial milestones outweigh the limited negatives, indicating constructive momentum with some execution and geographic diversification risks to monitor.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Nova Eye guided FY‑27 revenue (ex‑China) of USD 26.0–31.0 million (implying 15–37% growth versus FY‑26’s USD 23.7M, which was up 26% YoY and represents roughly a 26% CAGR since FY‑22’s USD 9.3M), reiterated it delivered EBITDA‑positive results in H2 FY‑26 and expects to be EBITDA‑positive for FY‑27 (no EBITDA figure given), and said July trading was running about 30% above prior run‑rate. Management highlighted the U.S. as the growth engine (U.S. revenue c. USD 18.6M, ~79% of sales, up ~30% YoY and +21% QoQ in the last quarter), ~20,000 procedures/year using the device (~4%–5% share of the ~30k–35k U.S. procedures per month), annualized revenue per rep ~USD 1.9M, and confirmed 2027 reimbursement drafts (~USD 542 surgeon / ~USD 2,204 facility) were broadly in line with 2026. They also noted China is a nascent market (down ~18% to roughly USD 200k), operating‑leverage improvements (sales & marketing OpEx fell from 76% to 52% of sales over time; corporate costs down from ~USD 1.7M to ~1.3M), and that current liquidity is sufficient to fund the FY‑27 plan (described as an unprecedented ~18 quarters of cash cover).
Nova Eye Medical Financial Statement Overview
Summary
Financial performance is mixed. Strengths include a strong gross margin recovery to 71.7% and robust revenue growth of 5.5%. However, the company remains unprofitable with a net loss margin of -12.4% and has a history of negative cash flows, though the cash burn rate has improved significantly. The balance sheet is a relative strength with low debt, but equity is eroding due to ongoing losses.
Income Statement
58NeutralBalance Sheet
72PositiveCash Flow
45Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.87M | 34.87M | 29.27M | 23.32M | 17.02M | 13.38M |
| Gross Profit | 25.01M | 25.01M | 20.07M | 20.19M | 842.00K | -765.00K |
| EBITDA | -2.21M | -2.21M | -8.98M | -5.98M | -14.65M | -7.89M |
| Net Income | -4.33M | -4.33M | -9.06M | -8.79M | -15.29M | -7.50M |
Balance Sheet | ||||||
| Total Assets | 21.59M | 21.59M | 26.50M | 29.88M | 30.36M | 36.63M |
| Cash, Cash Equivalents and Short-Term Investments | 964.00K | 964.00K | 5.05M | 6.15M | 7.42M | 8.00M |
| Total Debt | 2.39M | 2.39M | 3.02M | 3.35M | 1.53M | 1.94M |
| Total Liabilities | 7.31M | 7.31M | 7.54M | 8.55M | 7.17M | 6.23M |
| Stockholders Equity | 14.28M | 14.28M | 18.97M | 21.33M | 23.19M | 30.40M |
Cash Flow | ||||||
| Free Cash Flow | -3.36M | -3.36M | -6.58M | -8.31M | -7.52M | -10.27M |
| Operating Cash Flow | -3.12M | -3.12M | -6.15M | -7.86M | -6.72M | -4.68M |
| Investing Cash Flow | -388.00K | -388.00K | -364.00K | -325.00K | -800.00K | -4.58M |
| Financing Cash Flow | -657.00K | -657.00K | 5.56M | 6.91M | 6.82M | -402.00K |
Nova Eye Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EYE, the sentiment is Positive. The current price of 0.15 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.14, and above the 200-day MA of 0.13, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 61.63 is Neutral, neither overbought nor oversold. The STOCH value of 93.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EYE.
Nova Eye Medical Peers Comparison
Overall Rating
AU:COH69Neutral- AU:EYE57Neutral
AU:SOM56Neutral
AU:CMP54Neutral
AU:EMV45.75Neutral
AU:CBL38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:COH | 69Neutral | AUD 9.86B | 67.99 | 8.01% | 2.26% | -0.90% | -62.14% |
| AU:EYE | 57Neutral | AUD 44.16M | -10.20 | -28.79% | ― | 19.13% | 58.47% |
| AU:SOM | 56Neutral | AUD 63.73M | -23.97 | -5.44% | ― | 2.73% | 25.00% |
| AU:CMP | 54Neutral | AUD 49.94M | 218.18 | 0.93% | ― | 18.54% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:EMV | 46Neutral | AUD 138.97M | -16.16 | -46.84% | ― | ― | 20.40% |
| AU:CBL | 38Underperform | AUD 27.21M | -2.73 | -103.48% | ― | -22.43% | 15.02% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:EYE | Nova Eye Medical Ltd | 0.15 | 0.02 | 19.23% | |
| AU:COH | Cochlear Limited | 152.98 | -115.27 | -42.97% | |
| AU:CMP | Compumedics Limited | 0.24 | -0.10 | -30.43% | |
| AU:SOM | Somnomed Limited | 0.29 | -0.49 | -62.82% | |
| AU:EMV | EMvision Medical Devices Ltd. | 1.48 | -0.40 | -21.12% | |
| AU:CBL | Control Bionics Ltd. | 0.05 | -0.01 | -16.92% |
Nova Eye Medical Corporate Events
Nova Eye Medical to Present at Bell Potter Healthcare Conference
Nova Eye Medical will present at the virtual Bell Potter Healthcare Conference 2026 on 17 November 2026 at 3:00 pm AEDT, with Managing Director Tom Spurling providing an update on the business and participating in a live question-and-answer session....
Nova Eye Reports First iTrack Advance Sale in South Korea
Nova Eye Medical develops, manufactures and sells ophthalmic treatment technologies and devices, including iTrack Advance, a minimally invasive glaucoma surgical device, and the Molteno3 glaucoma drainage platform. Its products are used by eye surgeo...
Nova-Eye Medical Reports Director’s Indirect Shareholding Change
Nova-Eye Medical Limited is the entity named in the notice; the release does not provide information on its industry, products or market focus. Director Thomas George Duthy reported an indirect interest in 200,000 ordinary shares held through CIPA In...
Nova Eye Medical Reports New Director Has No Disclosed Interests
Nova Eye Medical Limited disclosed that Thomas George Duthy was appointed as a director on October 29, 2026. The notice reported that Duthy held no relevant securities interests, had no interests held through another party, and had no reportable cont...
Nova Eye Medical Discloses Final Director Interest as Rahmon Coupe Departs Board
Nova Eye Medical has reported the cessation of director Rahmon Coupe from the board as of 29 October 2026, detailing his final interests in the company’s securities. The notice confirms Coupe directly holds 1,341,200 ordinary shares and that a relate...
Nova Eye Investors Reject Director Re-election Despite Strong Backing for Other AGM Resolutions
Nova Eye Medical has released the results of its 29 October 2026 annual general meeting, showing shareholders strongly backed most board and governance proposals but rejected a key director re-election. The remuneration report and another ordinary re...
Nova Eye Medical Emphasizes Risk and Disclosure at 2026 AGM
Nova Eye Medical used its 2026 Annual General Meeting presentation to outline corporate information and risk considerations, while emphasizing that the material is not investment advice or a securities offering. The company highlighted that any state...
Nova Eye Medical boosts glaucoma device growth as profitability improves
Nova Eye Medical has reported a strong year of commercial progress, with FY26 sales rising 26% to US$23.7 million and positive EBITDA achieved in the second half, reflecting improving gross margins and narrowing operating losses. The company’s iTrack...
Nova Eye Medical accelerates sales growth and posts positive cash flow in September quarter
Nova Eye Medical reported a strong September quarter, with total sales rising 30% year-on-year to US$6.3 million and last-twelve-month revenues reaching US$25.1 million, marking an acceleration in growth versus the prior period. The company delivered...
Nova Eye Medical Schedules Investor Webinar to Review Quarterly Results
Nova Eye Medical will host an investor webinar on 2 November 2026 at 11:30 am AEDT, led by Managing Director Tom Spurling, to discuss the company’s September 2026 quarterly results. The online session, which allows participants to submit questions in...
Nova Eye Medical Director Mike Southard Resigns After Eight-Year Tenure
Nova Eye Medical has announced the resignation of director Mike Southard after eight years on the board, marking the departure of a key figure with deep experience in the global ophthalmic industry. Southard, a former Alcon Laboratories executive wit...
Nova Eye Medical sets October date for in-person AGM and proxy voting
Nova Eye Medical Limited has called its Annual General Meeting for shareholders to be held in person at The Kent Town Hotel in Adelaide on 29 October 2026 at 10:30 am local time. The company has set 27 October 2026 as the record date for voting eligi...
Nova Eye Medical Adds 45,809 Shares to ASX Quotation
Nova Eye Medical Limited has applied for quotation on the ASX of 45,809 new ordinary fully paid shares under its existing ticker EYE. The shares, issued on September 22, 2026, form part of previously announced transactions and will increase the compa...
Nova Eye Medical Plans Modest Share Placement on ASX
Nova Eye Medical Limited has notified the ASX of a proposed issue of 45,809 ordinary fully paid shares as part of a placement or similar capital raising. The new securities are scheduled to be issued on 21 September 2026, reflecting a modest expansio...
Nova Eye Medical Sets October AGM and Director Nomination Deadline
Nova Eye Medical has scheduled its Annual General Meeting for 29 October 2026 at 10:30am ACDT in Adelaide as an in-person event, with formal meeting materials to be circulated to shareholders in September. The meeting will include the election of dir...
Nova Eye Medical Director Spurling Increases On-Market Shareholding
Nova Eye Medical has disclosed a change in the shareholding of director Thomas Anthony Spurling, indicating increased direct equity exposure to the company. Spurling acquired 160,000 ordinary shares on market on 27 August 2026, lifting his direct hol...
Nova Eye Medical Lodges 2026 Corporate Governance Statement with ASX
Nova Eye Medical Limited has lodged its corporate governance statement for the year ended 30 June 2026 via its website, in line with ASX Listing Rule requirements. The statement outlines the extent to which the company adheres to the ASX Corporate Go...
Nova Eye Medical lifts FY26 sales and reaffirms growth outlook
Nova Eye Medical reported full-year sales of A$34.9 million for FY26, representing a 26% increase in constant currency and a marked improvement in profitability, including a positive EBITDA of A$0.2 million in the second half and a reduced full-year...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026